logo
ReposiTrak Adds 36 Food Manufacturers, Suppliers and Distributors for Traceability, Including the First North American Producer of Couscous

ReposiTrak Adds 36 Food Manufacturers, Suppliers and Distributors for Traceability, Including the First North American Producer of Couscous

Business Wire21 hours ago
SALT LAKE CITY--(BUSINESS WIRE)--ReposiTrak (NYSE:TRAK), the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, is proud to add 36 food manufacturers, suppliers and distributors to the queue of companies joining the ReposiTrak Traceability Network® (RTN). These companies will efficiently exchange intricate, FDA-required Key Data Elements (KDEs) for each Critical Tracking Event (CTE) in their supply chains, with the goal of meeting the growing traceability demands of their retail customers.
'Food manufacturers, suppliers and distributors need to act now to meet traceability demands of retailer and wholesaler customers, who require more data for more foods than the FDA, with swifter deadlines,' said ReposiTrak Chairman and CEO Randy Fields.
The suppliers who are preparing for traceability include the first North American producer of couscous whose offering has expanded to include short-cut pasta, quinoa, rice and Mediterranean blends, as well as a salsa manufacturer transforming cut fruits and vegetables into salsa varieties like green chili, pineapple and peach, in addition to enchilada sauces. Finally, a leading Canadian importer of foodservice products is joining, proving products such as feta, condiments and sauces, cut avocado and soy-based cheeses to restaurants.
'It's the industry – not the FDA – that's driving food traceability today,' said ReposiTrak Chairman and CEO Randy Fields. 'Food manufacturers, suppliers and distributors need to act now to meet the traceability demands of their retailer and wholesaler customers, who require more data for more foods than the FDA, with swifter deadlines.'
The ReposiTrak Traceability Network requires no additional hardware. Every traceability data file is checked using a 500+ point error detection process and ReposiTrak's U.S.-based team works with food manufacturers and suppliers to make corrections, so that the data is as complete and accurate as possible before it reaches their retail, wholesale or foodservice customers.
About ReposiTrak
ReposiTrak (NYSE: TRAK) provides retailers, suppliers, food manufacturers and wholesalers with a robust solution suite to help reduce risk and remain in compliance with regulatory requirements, enhance operational controls and increase sales with unrivaled brand protection. Consisting of three product families – food traceability, compliance and risk management and supply chain solutions – ReposiTrak's integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit https://repositrak.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CMB.TECH Business update Q2 2025 results
CMB.TECH Business update Q2 2025 results

Business Upturn

time11 minutes ago

  • Business Upturn

CMB.TECH Business update Q2 2025 results

Antwerp, Aug. 14, 2025 (GLOBE NEWSWIRE) — NV (NYSE: CMBT & Euronext: CMBT) ('CMBT', ' or 'the Company') will release its second quarter 2025 earnings prior to market opening on Thursday 28 August 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter. Due to the proximity of the expected closing date of the contemplated stock-for-stock merger between and Golden Ocean Group Limited ('Golden Ocean'), already provides preliminary figures related to the Q2 2025 results in this business update. Business update Q2 2025 results are scheduled to be announced by on 28 August 2025. Due to the proximity of the expected closing date of the contemplated stock-for-stock merger between and Golden Ocean, provides the following selected, preliminary figures related to Q2 2025 results: Key figures The most important preliminary key figures (unaudited) are: to be found in attachment. provides this information based on the current status of completing its Q2 2025 results and report. has not completed all its financial reporting and related consolidation, review and control procedures. The estimates provided are therefore subject to finalisation and change. Consequently, the finalised and approved Q2 2025 results, to be published by on 28 August 2025, may deviate from the above information. Details Q2 2025 earnings conference call on 28 August 2025 The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the 'Investor Relations' page of the website. The presentation, recording & transcript will also be available on this page. Webcast Information Event Type: Audio webcast with user-controlled slide presentation Event Date: 28 August 2025 Event Time: 8 a.m. EST / 2 p.m. CET Event Title: 'Q2 2025 Earnings Conference Call' Event Site/URL: To attend this conference call, please register via the following link. Telephone participants who are unable to pre-register may dial in to the respective number of their location (to be found here). The Phone conference ID is the following: 354 264 600# Announcement Q2 2025 results – 28 August 2025 About (all capitals) is a diversified and future-proof maritime group. We own and operate more than 150 seagoing vessels: crude oil tankers, dry bulk vessels, container ships, chemical tankers, offshore wind vessels & workboats. We also offer hydrogen and ammonia fuel to customers, through own production or third-party producers. The company is headquartered in Antwerp, Belgium, and has offices across Europe, Asia, United States and Africa. is listed on Euronext Brussels and the NYSE under the ticker symbol CMBT. More information can be found at Forward-Looking Statements Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbour protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. The words 'believe', 'anticipate', 'intends', 'estimate', 'forecast', 'project', 'plan', 'potential', 'may', 'should', 'expect', 'pending' and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. Attachment Business update Q2 2025 results Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Benchmark Raises Grupo Televisa (TV) Price Target on Q2 Cost Improvements
Benchmark Raises Grupo Televisa (TV) Price Target on Q2 Cost Improvements

Yahoo

timean hour ago

  • Yahoo

Benchmark Raises Grupo Televisa (TV) Price Target on Q2 Cost Improvements

Grupo Televisa, S.A.B. (NYSE:TV) is one of the best NYSE penny stocks to invest in now. On July 23, Benchmark lifted its price target on Grupo Televisa from $7.00 to $9.00 while maintaining a 'Buy' rating on the stock. The analysts cited cost improvements in Grupo Televisa's Mexico cable operations as reflected in the company's second-quarter 2025 earnings release. Benchmark also cited the TelevisaUnivision joint venture, in which Grupo Televisa holds a 43% stake, as a key factor in its decision. The joint venture reported a 10% increase in Adjusted Operating Income Before Depreciation and Amortization (OIBDA) despite a weak advertising market. Another factor is a 4.5% sequential improvement in the Mexican peso spot rate from the second-quarter 2025 moving average. Grupo Televisa, S.A.B. (NYSE:TV) is a Mexican multimedia conglomerate that owns and operates cable companies and satellite pay-TV systems. It delivers basic and premium TV subscriptions, internet, and mobile services through its Cable and Sky segments. The company also provides national advertising sales and data services via its fiber-optic network. While we acknowledge the potential of TV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Low-Priced Stocks to Buy Right Now and 11 Best Canadian Gold Stocks to Buy According to Hedge Funds. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Implantica publishes Interim Report January - June 2025 (Q2)
Implantica publishes Interim Report January - June 2025 (Q2)

Yahoo

timean hour ago

  • Yahoo

Implantica publishes Interim Report January - June 2025 (Q2)

VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA PMA Submission Completed - Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval) Additional preparations for U.S. market launch (pending FDA approval) included U.S. payer and reimbursement activities, finalizing new production facility of RefluxStop® in U.S. and launching our RCT (randomized clinical trial), as a heavyweight cornerstone in building global leadership in acid reflux care Positive NICE Guidance in the UK - UK's National Institute for Health and Care Excellence (NICE) issued positive guidance for the use of RefluxStop® in NHS hospitals for patients with ineffective esophageal motility (IOM/IEM), potentially transforming treatment access for millions and influencing global policy Significant events after the end of the period Landmark 5-Year Clinical Study Results - Two peer-reviewed articles were published in Surgical Endoscopy on our pivotal study results; one publication confirmed outstanding long-term safety and effectiveness outcomes, and the second publication highlighted RefluxStop®'s excellent outcomes in food passageway-related sequelae, which is common in standard of care Randomized Clinical Trial (RCT) Launch - First RCT comparing RefluxStop® with Nissen fundoplication; patient recruitment underway accumulating patients across participating hospitals. While this trial preparation led to a 20% year-on-year revenue decline for Q2, the impact is expected to ease once study recruitment stabilizes Spanish Market Expansion - Three new hospitals added, totaling 19 centers offering RefluxStop® in Spain, with a healthcare sytem receptive for new and better patient care, which is a fantastic launch since 2023 First UK National Users Meeting - Convened 21 top anti-reflux experts to discuss real-world results, operating technique and the opportunities arising from NICE's positive recommendation Financial summary second quarter 2025 Net sales decreased 22% to TEUR 433 (554) due to the launch of the randomized clinical trial with surgeons accumulating patients for the trial. Adjusted gross margin amounted to 90% (91%). Operating loss (EBIT) decreased to TEUR 4,525 (5,869). Loss after tax decreased to TEUR 5,448 (6,431). Basic and diluted loss per Class A share amounted to EUR 0.08 (0.09). Cash and short-term investments as at the end of the period of MEUR 56.3. First six months Net sales increased 2% to TEUR 1,178 (1,150). Adjusted gross margin amounted to 94% (91%). Operating loss (EBIT) decreased to TEUR 8,698 (12,956). Loss after tax decreased to TEUR 8,212 (9,903). Basic and diluted loss per Class A share amounted to EUR 0.12 (0.14). Telephone conference Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use the following link: Dial-in Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference. For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-14 08:00 CEST. About Implantica: Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. This information was brought to you by Cision The following files are available for download: Implantica Q2 2025_ENG Implantica publishes Interim Report Jan - Jun 2025 Q2 View original content:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store